Dermatological Safety Alert: This page covers supplement interactions with skin medications and dermatologic treatments. If you take prescription retinoids, immunosuppressants, photosensitizing medications, or are undergoing dermatological procedures, do not start any supplement without discussing it with your dermatologist or healthcare provider. Some interactions can worsen skin conditions or interfere with treatments.
This article is for informational purposes only and does not constitute medical advice. Always consult your dermatologist, physician, or healthcare provider before starting any supplement. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
HathawayMD.com Editorial Team | July 2026
Safety Overview: Teratogenic & Reproductive Risks in Skincare
Pregnancy creates a unique dermatological safety landscape. The developing fetus is particularly vulnerable to teratogenic (birth-defect-causing) exposures during organogenesis, the critical window spanning weeks 3–8 of gestation. Many widely prescribed and over-the-counter skincare actives cross the placental barrier or enter breast milk, creating documented risks of major malformations, growth restriction, and neurodevelopmental effects.
The FDA's historical categorization system (Categories A, B, C, D, X) has been replaced by the Pregnancy and Lactation Labeling Rule (PLLR), which provides narrative safety data. However, many older skincare products retain outdated pregnancy category labels. This creates patient confusion: a product labeled “Category C” may carry significant documented teratogenic risk but is legally permitted to carry that ambiguous classification.
The consequences of in-utero exposure to high-risk skincare ingredients include cleft palate (retinoids), skeletal malformations (salicylic acid at high doses), cardiac defects (some hydroxy acids), and permanent hearing loss (topical antibiotics containing aminoglycosides). For women planning pregnancy, discontinuation timing matters: retinoids require washout periods of 2–3 months; some ingredients require full pregnancy avoidance.
Who Is Most at Risk
Women in Reproductive Years Using Prescription Retinoids
Women ages 18–45 using tretinoin (Retin-A), adapalene (Differin), isotretinoin (Accutane), or tazarotene face the highest documented risk. Isotretinoin carries an absolute contraindication: pregnancy is categorized as a teratogenic certainty, with a 25–30% risk of major malformations including CNS, cardiac, thymic, and craniofacial defects. The iPLEDGE program mandates two negative pregnancy tests and two contraceptive methods for all isotretinoin users of reproductive capacity.
Women in First Trimester or Planning Conception
The first trimester (weeks 1–12) represents the highest-risk window for organ system formation. Women trying to conceive or in early pregnancy should assume all skincare actives are pregnancy-unsafe unless explicitly cleared. This includes those with history of acne, melasma, psoriasis, or rosacea—conditions often treated with teratogenic agents.
Women Using Multiple Skincare Actives
Combination regimens amplify risk. A patient using tretinoin + benzoyl peroxide + salicylic acid acid experiences compounded reproductive toxicity. Percutaneous absorption varies with formulation, application site, and skin barrier integrity, making cumulative dose difficult to predict.
Breastfeeding Mothers
Many pregnancy-unsafe ingredients transfer into breast milk. Salicylic acid, benzoyl peroxide, and some botanical actives achieve clinically significant milk concentrations, exposing nursing infants to potential metabolic and neurological effects.
Drug Interaction Deep Dive: Pregnancy-Unsafe Skincare Ingredients
RETINOIDS (All Forms): HIGH RISK
Specific agents: Tretinoin (Retin-A, generic), adapalene (Differin, Adaplene generic), tazarotene (Tazorac, Avage), isotretinoin (Accutane, Claravis, Myorisan), retinol, retinaldehyde, retinyl palmitate.
Mechanism: Retinoids activate retinoic acid receptors (RARs), which regulate gene expression during embryonic development. First-trimester exposure causes dose-dependent teratogenesis affecting the face, heart, CNS, thymus, and ears. Isotretinoin is the most teratogenic; even topical tretinoin carries significant risk due to systemic absorption, particularly on thin-skinned areas (face, neck, intertriginous zones).
Evidence base: Multiple prospective cohort studies and case registries (including the Accutane/isotretinoin pregnancy registry maintained by Roche and the active FDA teratogen surveillance system) confirm major malformation rates of 20–30% with isotretinoin and 5–15% with topical tretinoin in first trimester.
Clinical presentation of in-utero retinoid exposure:
- Craniofacial abnormalities: cleft palate, micrognathia, external ear malformations
- Cardiac defects: transposition of great vessels, tetralogy of Fallot
- CNS malformations: hydrocephalus, microcephaly, agenesis of corpus callosum
- Thymic hypoplasia or aplasia
- Sensorineural hearing loss
Timeline for discontinuation: The teratogenic window is weeks 3–8 (first trimester). However, retinoid levels in tissue remain elevated for weeks after discontinuation. Current obstetric guidance recommends discontinuing all retinoids at least 2–3 months before attempting conception to allow tissue clearance. For women already pregnant, retinoids should be discontinued immediately upon pregnancy confirmation.
Severity rating: HIGH RISK — Documented teratogen. Absolute contraindication in pregnancy and periconception period.
Monitoring & recommendations: Women of reproductive age using any retinoid should understand pregnancy contraindication. Counsel on two-form contraception (especially with isotretinoin, via iPLEDGE). If pregnancy is planned, discontinue retinoids 3 months before conception and confirm pregnancy test negative before restarting. If accidental pregnancy occurs during retinoid use, contact Teratogen Information Service (1-888-285-3410) immediately.
SALICYLIC ACID (Beta Hydroxy Acid): HIGH RISK at high doses; MODERATE RISK at low topical concentrations
Specific agents: Salicylic acid (BHA) in cleansers, toners, serums, peels; typically 0.5–2% in over-the-counter products; up to 20–30% in professional chemical peels.
Mechanism: Salicylic acid is a beta hydroxy acid that penetrates lipid-rich skin. It undergoes systemic absorption, particularly at high concentrations or with repeated application. At high doses, salicylates inhibit prostaglandin synthesis and platelet aggregation, potentially affecting fetal blood flow and skeletal development. Animal studies show skeletal abnormalities and decreased fetal weight at high doses; human epidemiological data remains limited but concerning.
Evidence base: The American Academy of Dermatology (AAD) and American College of Obstetricians and Gynecologists (ACOG) classify salicylic acid as a cautionary agent in pregnancy. A 2008 systematic review in Teratology concluded that high-dose salicylate exposure (>500 mg/day, typical of chronic aspirin therapy) increases risk of congenital anomalies, particularly during the second and third trimesters. Topical absorption of skincare-grade salicylic acid is lower than systemic aspirin; however, plasma salicylate levels can rise with intensive use (multiple daily applications, full-body coverage, or professional peels).
Clinical concern: Low-concentration cleansers (0.5–2%) used sparingly are considered lower-risk; high-concentration peels (20–30%) and intensive regimens (multiple daily applications) create uncertainty. The risk–benefit profile is unfavorable in pregnancy: acne and keratosis pilaris are not life-threatening conditions, and safer alternatives exist.
Severity rating: HIGH RISK (high-dose/frequency regimens); MODERATE RISK (low-concentration, occasional use). Safer to assume HIGH RISK and avoid entirely during pregnancy.
Monitoring & recommendations: Pregnant patients should discontinue salicylic acid products. Counsel non-pregnant women planning conception to taper salicylic acid use 1 month before attempting pregnancy. If accidental pregnancy occurs, advise discontinuation and contact obstetrician. Low-risk alternatives include glycerin-based cleansers, azelaic acid (see below), and sulfur-based products.
BENZOYL PEROXIDE: MODERATE TO HIGH RISK
Specific agents: Benzoyl peroxide (BPO) in cleansers, spot treatments, acne washes; typically 2.5–10% in over-the-counter products.
Mechanism: Benzoyl peroxide generates reactive oxygen species and free radicals, creating oxidative stress. Topical absorption is low (~5%), but systemic absorption occurs via skin degradation products. The metabolite benzoic acid is renally excreted. Animal teratogenicity studies are limited; human pregnancy outcome data are sparse. However, the mechanism of action (oxidative stress during organogenesis) raises theoretical concern for growth restriction and developmental toxicity.
Evidence base: No prospective randomized trials exist. A small case–control study (2010) found no increased major malformations with first-trimester benzoyl peroxide use; however, the sample size was insufficient to detect modest increases in rare birth defects. ACOG classifies BPO as Category C (under prior labeling), meaning risk cannot be ruled out. Current PLLR guidance suggests avoiding routine use in pregnancy.
Severity rating: MODERATE-TO-HIGH RISK — Limited human data but mechanistic concern warrants avoidance.
Monitoring & recommendations: Pregnant and periconception women should avoid benzoyl peroxide. For acne management during pregnancy, first-line agents are topical erythromycin, clindamycin (Cleocin), or azelaic acid. If accidental BPO exposure occurs, risk of major malformation is likely modest; contact Teratogen Information Service for reassurance.
AZELAIC ACID: MODERATE RISK (Preferred alternative for acne & rosacea in pregnancy)
Specific agents: Azelaic acid (Azelex, Finacea); typically 15–20% in skincare formulations.
Mechanism: Azelaic acid is a naturally occurring dicarboxylic acid that inhibits bacterial growth and reduces sebum production. It is minimally absorbed (<4% systemic absorption) and is rapidly metabolized and excreted in urine.
Evidence base: Multiple pregnancy registries and prospective cohort studies document no increased teratogenic risk with first-trimester azelaic acid exposure. The American College of Obstetricians and Gynecologists explicitly approves azelaic acid as a safer alternative for acne during pregnancy. Over 400 prospectively followed pregnancies show no pattern of birth defects.
Severity rating: LOW RISK — Preferred agent for pregnancy-associated acne and rosacea.
Monitoring & recommendations: Azelaic acid is the recommended first-line topical for acne, rosacea, and melasma during pregnancy. Counsel pregnant patients that this is an evidence-backed safer choice. Monitor for localized irritation (mild erythema and itching are common and typically resolve within 2–4 weeks).
HYDROXY ACIDS (AHAs: Glycolic Acid, Lactic Acid): MODERATE RISK
Specific agents: Glycolic acid (alpha hydroxy acid, AHA); lactic acid (milk acid); typically 5–15% in skincare, up to 20–70% in professional peels.
Mechanism: Hydroxy acids exfoliate the stratum corneum via keratin digestion. Low-concentration products have minimal systemic absorption; high-concentration peels can achieve measurable serum levels. In animal models, high-dose AHA exposure during pregnancy is associated with skeletal delays and reduced fetal weight, particularly during the second and third trimesters.
Evidence base: Human prospective pregnancy data are extremely limited. A small retrospective series (n=45) of women exposed to glycolic acid peels during pregnancy found no increased major malformations; however, the study was underpowered. ACOG guidance suggests caution and avoidance if possible, particularly with high-concentration peels.
Severity rating: MODERATE RISK — Low-concentration cleansers are lower-risk; professional peels warrant avoidance during pregnancy.
Monitoring & recommendations: Pregnant women should discontinue professional glycolic and lactic acid peels. Low-concentration cleansers (5–7%) used once weekly are considered acceptable by some maternal–fetal medicine specialists, but safer alternatives (gentle cleansers, azelaic acid) are preferred. If a patient becomes pregnant while using AHA products, discontinue and monitor for any signs of miscarriage or growth restriction at routine obstetric visits.
VITAMIN A DERIVATIVES (Retinyl Palmitate, Retinol): MODERATE-TO-HIGH RISK
Specific agents: Retinyl palmitate (common in moisturizers and sunscreens); retinol (in serums and anti-aging products); retinaldehyde (Prevage).
Mechanism: Retinyl palmitate and retinol are metabolic precursors to retinoic acid (the active form). Topical conversion to retinoic acid is limited (~1–5%); however, systemic absorption can occur, particularly on thin-skinned areas or in the presence of skin barrier disruption. Retinol is less potent than tretinoin but carries similar teratogenic potential if high enough systemic levels are achieved.
Evidence base: The FDA advises caution with retinol during pregnancy. A 2019 prospective cohort study (n=365) found that first-trimester retinol use was not associated with major malformations; however, some maternal–fetal medicine specialists recommend avoiding all retinoid-class compounds, including retinol and retinyl palmitate, out of an abundance of caution given the teratogenic certainty of prescription retinoids.
Severity rating: MODERATE-TO-HIGH RISK — Conservative approach: avoid all retinoid precursors during pregnancy.
Monitoring & recommendations: Pregnant and periconception women should avoid products listing retinyl palmitate, retinol, or retinaldehyde as active ingredients. Read ingredient lists carefully; retinyl palmitate is common in moisturizers marketed as “anti-aging” and is often not prominently disclosed. Safer alternatives include vitamin C (L-ascorbic acid), niacinamide, and hyaluronic acid.
HYDROQUINONE: MODERATE RISK
Specific agents: Hydroquinone (Esoterica, Neostrata, generic formulations); typically 2–4% in over-the-counter products, up to 4–6% prescription strength.
Mechanism: Hydroquinone inhibits melanin synthesis by suppressing tyrosinase activity. Percutaneous absorption is 35–45%, meaning significant systemic exposure occurs, particularly with full-face application. In animal models at high doses, hydroquinone caused developmental delays and fetal toxicity. Human pregnancy outcome data are limited.
Evidence base: The FDA pregnancy category for hydroquinone was historically C (risk cannot be ruled out). A small retrospective review found no increased birth defects with first-trimester hydroquinone use; however, prospective data are insufficient. ACOG guidance suggests caution and preferentially using alternative melasma treatments (azelaic acid, laser therapy post-pregnancy) during pregnancy.
Severity rating: MODERATE RISK — Avoid routine use. Azelaic acid is preferred for melasma during pregnancy.
Monitoring & recommendations: Pregnant women with melasma should discontinue hydroquinone and transition to azelaic acid (15–20%) as first-line therapy. Protective sun care (UPF 50+, daily reapplication) is critical, as UV exposure worsens melasma. If accidental hydroquinone exposure occurs during pregnancy, the risk of teratogenesis is low; reassure the patient and continue routine prenatal monitoring.
BOTANICAL ACTIVES (Vitamin C, Plant Polyphenols, Botanical Extracts): THEORETICAL TO LOW RISK
Specific agents: L-ascorbic acid (vitamin C serums); ferulic acid; resveratrol; green tea extract (EGCG); retinol alternatives like bakuchiol; other herbal extracts.
Mechanism: Most botanical actives work through antioxidant or anti-inflammatory pathways. L-ascorbic acid (vitamin C) is water-soluble with minimal systemic absorption. Bakuchiol is a retinol alternative derived from the babchi plant; it activates retinoid-responsive genes but does not bind retinoic acid receptors directly, potentially reducing teratogenic risk compared to true retinoids.
Evidence base: Human pregnancy outcome data for most botanical skincare actives are absent or extremely limited. Bakuchiol is emerging as a pregnancy-safer retinol alternative; preliminary in vitro and animal data suggest lower teratogenic potential than retinol, though human pregnancy studies are not yet published. Vitamin C is widely considered safe in pregnancy at typical skincare concentrations.
Severity rating: THEORETICAL RISK — Insufficient human data; individual ingredients require case-by-case assessment.
Monitoring & recommendations: Counsel pregnant patients that most botanical actives in skincare are considered lower-risk than prescription retinoids or salicylic acid, but human safety data are limited. Recommend discussing specific products with obstetric provider. Vitamin C (L-ascorbic acid) serums at 10–20% are considered acceptable. Bakuchiol is marketed as a retinol alternative and may be safer, but pregnancy-specific data are not yet robust. Avoid botanical products containing high concentrations of essential oils (some are potentially uterotonic or neurotoxic at high doses).
Interaction Summary Table
| Skincare Ingredient | Pregnancy Risk Category | Primary Concern | Severity | Recommendation |
|---|---|---|---|---|
| Isotretinoin (Accutane) | Absolute contraindication (25–30% malformation risk) | Craniofacial, cardiac, |